BRPI0407781A - aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes - Google Patents

aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes

Info

Publication number
BRPI0407781A
BRPI0407781A BRPI0407781-4A BRPI0407781A BRPI0407781A BR PI0407781 A BRPI0407781 A BR PI0407781A BR PI0407781 A BRPI0407781 A BR PI0407781A BR PI0407781 A BRPI0407781 A BR PI0407781A
Authority
BR
Brazil
Prior art keywords
ribavirin
interferon beta
combined application
demyelinating diseases
application
Prior art date
Application number
BRPI0407781-4A
Other languages
English (en)
Inventor
Giampiero De Luca
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BRPI0407781A publication Critical patent/BRPI0407781A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"APLICAçãO COMBINADA DE RIBAVIRINA E INTERFERON BETA EM DOENçAS DESMIELINIZANTES". A presente invenção é no campo dos distúrbios neurológicos. Refere-se à aplicação de um composto de fórmula (I) em combinação com um interferon (IFN) para a fabricação de um medicamento para tratamento e/ou prevenção de uma doença desmielinizante. Em particular, refere-se à aplicação de uma combinação de Ribavirina e IFNbeta para tratamento e/ou prevenção de uma doença desmielinizante, tal como esclerose múltipla.
BRPI0407781-4A 2003-02-25 2004-02-24 aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes BRPI0407781A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100459 2003-02-25
PCT/EP2004/050202 WO2004075903A1 (en) 2003-02-25 2004-02-24 Combined use of ribavirin and interferon beta in demyelinating diseases

Publications (1)

Publication Number Publication Date
BRPI0407781A true BRPI0407781A (pt) 2006-02-14

Family

ID=32921601

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407781-4A BRPI0407781A (pt) 2003-02-25 2004-02-24 aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes

Country Status (12)

Country Link
US (1) US20060276419A1 (pt)
EP (1) EP1596873A1 (pt)
JP (1) JP2006518725A (pt)
KR (1) KR20060002758A (pt)
CN (1) CN1761471A (pt)
AU (1) AU2004216485B2 (pt)
BR (1) BRPI0407781A (pt)
CA (1) CA2515210A1 (pt)
EA (1) EA010801B1 (pt)
MX (1) MXPA05008998A (pt)
NO (1) NO20054158L (pt)
WO (1) WO2004075903A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2805723T3 (pl) * 2004-12-22 2018-04-30 Merck Serono Sa Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
CA2626056A1 (en) * 2005-11-18 2007-05-24 Ares Trading S.A. Interferon in influenza
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
US10374993B2 (en) 2017-02-20 2019-08-06 Snap Inc. Media item attachment system
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
EA035792B1 (ru) * 2018-06-21 2020-08-11 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Лекарственное средство пролонгированного действия для лечения рассеянного склероза (варианты)
US11265281B1 (en) 2020-01-28 2022-03-01 Snap Inc. Message deletion policy selection
IL301246A (en) 2020-09-10 2023-05-01 Merck Patent Gmbh Treatment regimen with cladribine
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4307883A1 (en) * 1992-03-12 1993-09-23 Westarp Martin Egon Dr Med Use of anti-retroviral substances - to treat motor-neuronal diseases
EP1132393B1 (en) * 1996-10-16 2003-04-09 ICN Pharmaceuticals, Inc. L-Ribavirin and uses thereof
WO2000030656A1 (en) * 1998-11-20 2000-06-02 The Salk Institute For Biological Studies Neuron stimulation by ribavirin, and analogs thereof
US6495677B1 (en) * 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds

Also Published As

Publication number Publication date
WO2004075903A1 (en) 2004-09-10
EA010801B1 (ru) 2008-12-30
JP2006518725A (ja) 2006-08-17
NO20054158L (no) 2005-09-07
AU2004216485A1 (en) 2004-09-10
US20060276419A1 (en) 2006-12-07
EA200501344A1 (ru) 2006-02-24
CN1761471A (zh) 2006-04-19
EP1596873A1 (en) 2005-11-23
AU2004216485B2 (en) 2009-06-11
CA2515210A1 (en) 2004-09-10
KR20060002758A (ko) 2006-01-09
MXPA05008998A (es) 2005-10-18

Similar Documents

Publication Publication Date Title
BR0314760A (pt) Compostos orgânicos
BRPI0415167A (pt) composto de amina como ligandos de canal de ìon e usos dos mesmos
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2003256755A1 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
GB0129260D0 (en) Pharmaceutical compositions and their uses
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
WO2005067900A3 (en) Azabenzofuran substituted thioureas as inhibitors of viral replication
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0411451A (pt) formas de dosagens orais de memantina
PT1448564E (pt) Composto do tipo indolizina substituidos e metodos de utilizacao
BR0308154A (pt) Emprego de epotilonas no tratamento de doenças cerebrais associadas com processos proliferativos
MXPA05008998A (es) Uso combinado de ribavirina e interferon beta en enfermedades desmielinizantes.
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/7056, 38/21; A61P 25/00

Ipc: A61K 31/7056 (2011.01), A61K 38/21 (2011.01), A61P

B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.